Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells

Auranofin has been developed as antirheumatic drugs, which is currently under clinical development for the treatment of chronic lymphocytic leukemia. Previous report showed that auranofin induced apoptosis by enhancement of annexin A5 expression in PC-3 cells. To understand the role of annexin A5 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shin, Dong-Won, Kwon, Yeo-Jung, Ye, Dong-Jin, Baek, Hyoung-Seok, Lee, Joo-Eun, Chun, Young-Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340543/
https://www.ncbi.nlm.nih.gov/pubmed/27956714
http://dx.doi.org/10.4062/biomolther.2016.223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340543/
https://www.ncbi.nlm.nih.gov/pubmed/27956714
http://dx.doi.org/10.4062/biomolther.2016.223

Ejemplares similares